FDA orders GLP-1 makers to warn of rare eye condition

· Health · United States

The FDA told makers of GLP-1 drugs to update their product labels to reflect an increased risk of a rare eye condition that can lead to blindness, Endpoints News and STAT reported. STAT described the condition as sometimes called an "eye stroke." The label change affects the increasingly crowded class of GLP-1 medicines used for diabetes and obesity, which includes products such as Ozempic and Wegovy. The warning adds a safety consideration for a drug category that has expanded rapidly.

Why it matters：A class-wide safety label change affects every GLP-1 manufacturer and could influence prescribing as the obesity market keeps growing.

Key points

  • The FDA required label updates for GLP-1 drugmakers.
  • The rare condition is sometimes called an "eye stroke."

Sources (original reporting)

More stories from this day